NCT05020249View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

September 5, 2022

Study Completion Date

September 6, 2022

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

bimekizumab

Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

OTHER

Placebo

Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.

Trial Locations (9)

Unknown

Ps0032 20211, Bucheon-si

Ps0032 20214, Busan

Ps0032 20215, Gwangju

Ps0032 20208, Seongnam-si

Ps0032 20210, Seongnam-si

Ps0032 20104, Seoul

Ps0032 20138, Seoul

Ps0032 20213, Seoul

Ps0032 20216, Seoul

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT05020249 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter